Altre lingue Kineta, Inc.

Azioni

KA

US49461C1027

Mercato chiuso - Nasdaq Altri mercati azionari 22:30:01 05/07/2024			Variaz. 5gg	Var. 1 gen.
0,6068 ^USD	+8,09%		+14,34%	-83,28%

15/05	Kineta, Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI
08/04	Kineta, Inc. riferisce i primi dati di risposta clinica all'AACR 2024 del suo studio clinico Vista-101 di Fase 1/2 in corso	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Kineta : Failure to Satisfy Listing Rule - Form 8-K	30/05
Kineta, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities	15/05
Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial	08/04
Kineta, Inc. Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 Vista-101 Clinical Trial	08/04
Earnings Flash (KA) KINETA Posts 2023 Revenue $5.4M	21/03
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update	21/03
KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported	12/03
Kineta, Inc. Announces an Update on Its Ongoing Vista-101 Phase 1/2 Clinical Trial Evaluating Kva12123	12/03
Top Midday Decliners	29/02
Kineta Announces Restructuring and Exploration of Strategic Alternatives	29/02
Kineta, Inc. Terminates Employment of Pauline Kenny as General Counsel and Secretary	29/02
Kineta, Inc. Terminates Employment of Shawn Iadonato as CEO	29/02
Kineta, Inc. Announces Restructuring and Workforce Reduction	29/02
Kineta Announces Exploration of Strategic Alternatives	29/02
Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium	22/02
Kineta to Present at Upcoming Investor Conferences	14/02
Kineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat Series	07/02
Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors	17/01
Kineta, Inc. Announces Update on Ongoing Vista-101 Phase 1/2 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Tumor Activity	17/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Kineta, Inc.

Azioni

KA

US49461C1027

Altre lingue

Filtri